Hair loss

Hairline Ink Announces Opening of New Location in Austin and Release of "The Hair Loss Handbook"

Retrieved on: 
Wednesday, July 31, 2019
Human hair, Organ systems, Human body, Body modification, Hair tattoo, Hairstyles, Hair diseases, Plastic surgery, Hair loss, Hair, Permanent makeup

The Hair Loss Handbook consists of over 120 pages of valuable information on hair loss, including the causes, the benefits of scalp micropigmentation (SMP), hair loss myths, so-called "cures," and more.

Key Points: 
  • The Hair Loss Handbook consists of over 120 pages of valuable information on hair loss, including the causes, the benefits of scalp micropigmentation (SMP), hair loss myths, so-called "cures," and more.
  • "The Hair Loss Handbook is fabulous," said Shauna Magrath, owner of Beauty Ink Gallery, one of Canada's top cosmetic tattoo studios.
  • Hairline Ink has provided thousands of people with a permanent solution to hair loss, and the team is excited to bring their extensive experience to Austin.
  • The team at Hairline Ink encourages anyone in Texas dealing with hair loss to visit their newest office inAustin by booking a free consultation.

Global Alopecia Treatment Market, 2019-2024: Increasing R&D Initiatives and New Product Launches and Approvals

Retrieved on: 
Tuesday, July 23, 2019
Organ systems, Hair diseases, Human hair, RTT, Autoimmune diseases, Hair loss, Alopecia areata, Pattern hair loss, Management of hair loss, Non scarring hair loss

The launches of such novel products in the market is expected to drive the global alopecia treatment market growth in the near future.

Key Points: 
  • The launches of such novel products in the market is expected to drive the global alopecia treatment market growth in the near future.
  • As per the scope of the report, Alopecia Treatment (Hair Loss) are the drugs which are indicated for the treatment of alopecia.
  • Female is Expected to Hold Largest Share of Global Alopecia Treatment (Hair Loss) Market, Over the forecast period
    About one-third of women experience hair loss (alopecia) at some time in their lives.
  • It is one of many recognized forms of alopecia, alopecia areata is the second most common form after androgenetic alopecia.

United States Alopecia Market Landscape 2019: Treatment, Pipeline, Epidemiology, Key Products, Valuations, Drug Sales and Market Shares 2014-2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 11, 2019
Pharmaceutical, Health, Other Health, Organ systems, Hair diseases, Human hair, Business, RTT, Articles, Hair loss, Market share, Market analysis, Market

The "US Alopecia Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Alopecia Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.
  • US Alopecia Market and Competitive Landscape Highlights - 2019, provides comprehensive insights into Alopecia pipeline products, Alopecia epidemiology, Alopecia market valuations and forecast, Alopecia drugs sales and competitive landscape in the US.
  • The research is classified into seven sections- Alopecia treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Find out how the market advanced from 2014 and forecast to 2024
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Alopecia products

Mereltä Unveils First Annual "Truth about Hair and Scalp Care" Survey Results

Retrieved on: 
Tuesday, June 25, 2019
Organ systems, Human hair, Hairdressing, Hair diseases, Hair care, Hygiene, Hair loss, Hair, Scalp

BOSTON, June 25, 2019 /PRNewswire-PRWeb/ -- Merelt , a hair care brand rooted in science and inspired by nature, today released the findings of its first annual "Truth about Hair and Scalp Care" survey.

Key Points: 
  • BOSTON, June 25, 2019 /PRNewswire-PRWeb/ -- Merelt , a hair care brand rooted in science and inspired by nature, today released the findings of its first annual "Truth about Hair and Scalp Care" survey.
  • Broken down by gender, the survey results show: 34 percent of men selected "hair loss" and 32 percent selected "hair thinning" as their biggest hair/scalp concern.
  • For women, 33 percent of respondents selected "hair thinning" and 26 percent selected "hair loss" as their biggest hair/scalp concern.
  • "The scalp is the source of hair and therefore nurturing the scalp promotes healthier and thicker hair strands long term.

MONAT Efficacy Test Results Presented by President of the American Hair Research Society at 24th World Congress of Dermatology

Retrieved on: 
Wednesday, June 26, 2019
Women, Health, Other Health, Retail, Cosmetics, Consumer, Organ systems, Hairdressing, Human hair, Trichoscopy, Integumentary system, Hair loss, Hairstyling product, Hair, Hairstyles, Antonella Tosti, Women, Health, Other Health, Retail, Cosmetics, Consumer, Hairdressing, Organ systems, Human hair, Trichoscopy, Integumentary system, Hair loss, Hairstyling product, Hair, Hairstyles, Antonella Tosti

The tests were performed on normal, virgin hair and chemically damaged hair, i.e.

Key Points: 
  • The tests were performed on normal, virgin hair and chemically damaged hair, i.e.
  • The tests results showed that MONATs products:
    Specifically, the results of the tensile (strength) tests show that the tested hair products improved combability by reducing the mechanical resistance (combing force) of the hair.
  • In particular, the products did not cause hair breakage or loss of hair flexibility even when used on bleached, damaged hair.
  • Dr. Tosti is a founding member and past president of the European Hair Research Society, and Secretary and Treasurer of the North American Research Society, as well as a founding member and secretary of the International Society of Trichoscopy.

Follica Announces Progression to Pivotal Study Following Positive Interim Data in Male Androgenetic Alopecia

Retrieved on: 
Thursday, June 13, 2019
Health, Biotechnology, Clinical trials, Medical devices, Organ systems, Hair diseases, Human hair, Health, Pattern hair loss, Hair loss, Clinical trial

Follica, Inc. (Follica), a clinical-stage biotech developing a regenerative platform for hair growth, today announced positive interim data from an ongoing safety and optimization study to treat hair loss in male androgenetic alopecia.

Key Points: 
  • Follica, Inc. (Follica), a clinical-stage biotech developing a regenerative platform for hair growth, today announced positive interim data from an ongoing safety and optimization study to treat hair loss in male androgenetic alopecia.
  • A pivotal study is expected to initiate at the end of 2019 subject to continued safety and efficacy in the optimization study.
  • In addition to the ongoing safety and optimization study, Follica has proof-of-concept data from prior clinical studies using prototype devices with different treatment parameters and therapeutic compounds.
  • Follica is conducting an ongoing optimization trial, with a pivotal study in androgenetic alopecia expected to begin at the end of Q4 2019.

Concert Pharmaceuticals Completes Enrollment in Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata

Retrieved on: 
Wednesday, June 5, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Organ systems, Hair diseases, Human hair, RTT, Health, Clinical pharmacology, Hair loss, Alopecia areata, Clinical trial

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.
  • The open label trial (NCT03811912) is a randomized, multi-center study to evaluate the efficacy and tolerability of once-daily versus twice-daily dosing ofCTP-543, in 57 adult patients with chronic, moderate-to-severe alopecia areata.
  • A second open label trial (NCT03941548) to evaluate once-daily compared to twice-daily oral dosing was initiated in May 2019 and is currently enrolling patients.
  • Concert Pharmaceuticals Inc., theCoNCERT Pharmaceuticals Inc.logo and DCE Platform are registered trademarks ofConcert Pharmaceuticals, Inc. All other trademarks are those of their respective owners.

Silicon Valley Hair Institute Announces Post on Taking Bay Area Hair Loss Reviews Seriously Yet with a Grain of Salt

Retrieved on: 
Sunday, May 26, 2019
Physical sciences, Chemistry, California, Community websites, Review websites, Hair diseases, Human hair, Yelp, Hair loss, Hair, Silicon, San Francisco Bay Area

SAN FRANCISCO, May 26, 2019 /PRNewswire-PRWeb/ -- The Bay Area leader in hair loss restoration, Silicon Valley Hair Institute, is proud to announce a new informative post for persons considering hair loss surgery.

Key Points: 
  • SAN FRANCISCO, May 26, 2019 /PRNewswire-PRWeb/ -- The Bay Area leader in hair loss restoration, Silicon Valley Hair Institute, is proud to announce a new informative post for persons considering hair loss surgery.
  • The post explains how to find reviews of hair loss treatments, read reviews seriously, yet take them all with a grain of salt.
  • Bay Area hair loss reviews on sites such as Google, Yelp, or Healthgrades should be taken with a "grain of salt" until further investigation.
  • For these reasons, Silicon Valley Hair Institute has announced a new post about Bay Area hair loss reviews on sites such as Yelp or Google.

Overcoming Hair Loss and Wildfires, An Inspiring Theradome Story

Retrieved on: 
Saturday, May 25, 2019
Women, Health, Medical devices, Retail, Cosmetics, Specialty, Consumer, Branches of biology, Human hair, Organ systems, Anatomy, Blood products, Hair diseases, Human hair growth, Hair loss, Laser, Hair follicle, Platelet-rich plasma, Platelet

While exploring options to stop and reverse her hair loss, Emily heard about a treatment called platelet-rich plasma (PRP) injections.

Key Points: 
  • While exploring options to stop and reverse her hair loss, Emily heard about a treatment called platelet-rich plasma (PRP) injections.
  • Laser hair growth therapy also works to stimulate hair follicles but by delivering a concentrated dose of energy with a precise wavelength of light.
  • Of her experience with Theradome and laser hair growth therapy, she said, I wish that more people dealing with hair loss knew about it, it really does work and I believe in it!
  • The laser helmets developed by Tamim Hamid can minimize shedding, thicken existing hair and promote new hair growth.

Daytime Emmys Join MONAT’s ‘Healthy Hair Revolution’

Retrieved on: 
Thursday, May 16, 2019
Seniors, Women, Catalog, Entertainment, TV and Radio, Luxury, Online Retail, Home Goods, Baby, Maternity, Teens, Retail, Cosmetics, Fashion, Specialty, Consumer, Family, MEN, Hairdressing, Organ systems, Health, Self-care, Hair care, Shampoo, Paraben, Hair loss, Hair

View the full release here: https://www.businesswire.com/news/home/20190516005268/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190516005268/en/
    MONAT's Daytime Emmy Gifts (Photo: Business Wire)
    REJUVENIQEOil Intensive , an oil so pure and versatile, it can be used in multiple ways to improve skin and hair.
  • REJUVABEADS by MONAT , a targeted solution for stressed tresses that temporarily mends split ends and damaged areas along the hair shaft.
  • With products addressing signs of aging in hair, including thinness, brittleness, breakage and loss of hair density, MONATs shampoos, conditioners, serums, and treatments protect the hair and promote optimal hair growth and health while providing aesthetic benefits such as shine and volume.
  • Abiding by MONATs strict standards for its hair care products, all of the companys products are free from harmful colors and fragrances, phthalates, and parabens.